 Leishmania is a protozoan parasite that causes a variety of diseases in humans. It is transmitted through a bite of certain species of sandfly, and can cause either fatal visceral leishmaniasis, self-healing cutaneous leishmaniasis, or mucocutaneous leishmaniasis. Traditional treatment options include generic pandevalent antimonials, but they are often ineffective due to drug resistance and severe side effects. Alternatives such as Amphotericin B, Miltifocin, and Paramomycin have been approved, but they too have drawbacks. There is currently no vaccine available, so first-line chemotherapies like pandevalent antimonials, pentamidine, and Amphotericin B remain the only option for treating infected individuals. These drugs are expensive and toxic, leading to the need for better alternatives. Recently, researchers have begun to explore other methods of treatment, such as targeting novel drugs using bioinformatics and cellular and biochemical analysis, by identifying unique enzymes and biochemical pathways in leishmania. This article was authored by Ranjit Singh, Muhammad Kashif, Pratik Srivastava, and others. We are article.tv. Links in the description below.